SNSE

MKT CAP:$43M

Sensei Biotherapeutics, Inc.

Market Cap

$43M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$32.62+$22.97 (+238.03%)

Apr 23, 2026

Company Details

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach t...

CEO

Christopher W. Gerry

IPO Date

Feb 4, 2021

Website

www.senseibio.com

Key Metrics TTM

Revenue

-$5M

— YoY

Net Income

-$21M

EPS (Diluted)

-$16.72

Free Cash Flow

-$20M

Revenue / Share

-$3.85

Gross Margin

0.0%

Operating Margin

459.5%

Net Margin

434.7%

FCF Margin

422.0%

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 12, 2026

PENDING

FY 2025

Mar 30, 2026

$0EPS -$16.72

Q4 2025

Mar 30, 2026

$0EPS -$8.92

Q3 2025

Nov 14, 2025

-$5MEPS -$3.62

Q2 2025

Aug 5, 2025

$0EPS -$3.91

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$448.0K	-$12M
Q2 22	$0	-$440.0K	-$11M
Q3 22	$0	-$451.0K	-$14M
Q4 22	$0	-$469.0K	-$12M
Q1 23	$0	$0	-$11M
Q2 23	$0	-$491.0K	-$10M
Q3 23	$0	-$455.0K	-$8M
Q4 23	$0	-$135.0K	-$8M
Q1 24	$0	-$137.0K	-$9M
Q2 24	$0	-$135.0K	-$8M
Q3 24	$0	-$140.0K	-$8M
Q4 24	$0	-$139.0K	-$7M
Q1 25	$0	-$30.0K	-$7M
Q2 25	$0	-$37.0K	-$5M
Q3 25	-$5M	$0	-$5M
Q4 25	$0	$67.0K	-$5M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$11M	-$11M
Q2 22	-$12M	-$12M
Q3 22	-$7M	-$7M
Q4 22	-$10M	-$10M
Q1 23	-$12M	-$12M
Q2 23	-$9M	-$9M
Q3 23	-$5M	-$5M
Q4 23	-$6M	-$6M
Q1 24	-$8M	-$8M
Q2 24	-$6M	-$6M
Q3 24	-$5M	-$5M
Q4 24	-$6M	-$6M
Q1 25	-$7M	-$7M
Q2 25	-$6M	-$6M
Q3 25	-$4M	-$4M
Q4 25	-$4M	-$4M

Capital Expenditures

Quarter	CapEx
Q1 22	$19.0K
Q2 22	$52.0K
Q3 22	$250.0K
Q4 22	$0
Q1 23	$151.0K
Q2 23	$29.0K
Q3 23	$0
Q4 23	$0
Q1 24	$37.0K
Q2 24	$109.0K
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$16.0K
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+56.7%
Q2 22	—	+9.5%
Q3 22	—	+35.1%
Q4 22	—	+27.3%
Q1 23	—	-11.8%
Q2 23	—	-4.9%
Q3 23	—	-44.5%
Q4 23	—	-32.0%
Q1 24	—	-20.7%
Q2 24	—	-23.5%
Q3 24	—	+1.1%
Q4 24	—	-10.1%
Q1 25	—	-16.7%
Q2 25	—	-33.1%
Q3 25	—	-100.0%
Q4 25	—	-32.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	—
Q2 22	$1M	—
Q3 22	$1M	—
Q4 22	$0	—
Q1 23	$1M	—
Q2 23	$0	—
Q3 23	$1M	—
Q4 23	$1M	—
Q1 24	$1M	—
Q2 24	$795.0K	—
Q3 24	$733.0K	—
Q4 24	$391.0K	—
Q1 25	$461.0K	—
Q2 25	$264.0K	—
Q3 25	$254.0K	—
Q4 25	$295.0K	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$7M	—	$5M
Q2 22	$6M	—	$4M
Q3 22	$9M	—	$4M
Q4 22	$7M	—	$5M
Q1 23	$5M	$6M	—
Q2 23	$4M	—	$5M
Q3 23	$4M	—	$3M
Q4 23	$4M	—	$4M
Q1 24	$5M	$4M	—
Q2 24	$5M	—	$3M
Q3 24	$5M	—	$3M
Q4 24	$4M	—	$3M
Q1 25	$4M	—	$4M
Q2 25	$3M	—	$3M
Q3 25	$3M	$2M	—
Q4 25	$2M	$3M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$9M	$128M	$136M
Q2 22	$10M	$114M	$124M
Q3 22	$11M	$105M	$117M
Q4 22	$18M	$89M	$107M
Q1 23	$8M	$87M	$96M
Q2 23	$10M	$69M	$79M
Q3 23	$11M	$61M	$72M
Q4 23	$13M	$53M	$66M
Q1 24	$11M	$47M	$58M
Q2 24	$12M	$40M	$52M
Q3 24	$19M	$28M	$47M
Q4 24	$10M	$31M	$41M
Q1 25	$10M	$24M	$34M
Q2 25	$13M	$16M	$29M
Q3 25	$11M	$14M	$25M
Q4 25	$9M	$13M	$21M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	31M	+0.2%	+62.1%
Q2 22	31M	+0.2%	+0.4%
Q3 22	31M	+0.1%	+0.4%
Q4 22	31M	+0.1%	+0.5%
Q1 23	31M	+0.4%	+0.7%
Q2 23	31M	-1.2%	-0.6%
Q3 23	26M	-16.4%	-16.9%
Q4 23	25M	-1.9%	-18.6%
Q1 24	25M	+0.1%	-18.8%
Q2 24	25M	+0.2%	-17.7%
Q3 24	25M	+0.2%	-1.4%
Q4 24	25M	+0.1%	+0.5%
Q1 25	25M	+0.1%	+0.6%
Q2 25	1M	-95.0%	-95.0%
Q3 25	1M	+0.0%	-95.0%
Q4 25	1M	-0.0%	-95.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	56
Q2 22	$0	56
Q3 22	$0	56
Q4 22	$0	28
Q1 23	$0	28
Q2 23	$0	28
Q3 23	$0	28
Q4 23	$0	27
Q1 24	$0	27
Q2 24	$0	27
Q3 24	$0	27
Q4 24	$0	14
Q1 25	$0	14
Q2 25	$0	14
Q3 25	-$346.5K	14
Q4 25	$0	10K

Revenue / Employee